batzem,
I prefer the longer route, lets see how the improved mp-470 and sgi-1776 perform. $5 may look good right now, but then that's where it ends. S110 being pointed at solid tumors, would be a huge development for a drug that we know works in cancer. Listen to the call again, manuso hinted that they're working to partner Sgi-1252 and 2009 aim is to breakeven on the low side.
We have 3 conferences on mp-470 where data will be rolled out. I believe supg has received offers on several of these drugs, the upfront fees go way up the more they can present. We could be talking 50M up front fees. Dr. Manuso stated that several LARGE companies are interested in CLIMB in some capacity.
Dacogen continued growth is the key here. JNJ is selling this drug in 15 countries and soon to be 30.